Ellington Healthcare Partners I, L.P. is a venture capital fund guided by the deep and significant expertise of the members of its General Partner, NSIP LLC, all of whom are members of Ellington Healthcare Asset Management LLC, the Manager. NSIP and Ellington Healthcare Asset Management are currently chaired by Tommy G. Thompson, former Secretary of the U.S. Department of Health and Human Services. The Fund is seeking to invest in start-up and early stage companies with unique therapeutic products and devices.
Targeted investments in the areas of Oncology, Nanotechnologies, Adult Stem Cells, and Bone Marrow Derived Cells that demonstrate potential breakthroughs in the treatment of disease or possess strong advantages over currently marketed products. Ellington will seek to be a lead or co-investor, making commitments in multi-stages up to $25 million while seeking returns on invested capital superior to those generally obtainable in the public equity markets.
The Fund’s team of Science Partners comprises three world-renowned experts in their fields, Drs. Elfenbein, Sackstein and Kester, who provide Ellington unique insight and access into the rapidly developing advances in Nanotechnologies and Adult Stem Cell research and applications. The Fund believes that Nanotechnology and Adult Stem Cell platforms provide some of the greatest economic potential in medical science. Leveraging the expertise of its Science Partners, who are at the core of the information flow in these arenas, the Fund will focus its investments in opportunities with these attributes:
Breakthrough treatments or devices where none currently exist
Better efficacy via improvements in formulations
Safety advantages over existing approved treatments
Strong intellectual property
Products or platform technologies with compelling market potential relative to the company’s valuation
High margin products with a total market potential of in excess of $100 million
Clear or established reimbursement protocol.
Nanotechnology holds great promise in optimizing pharmaceutical efficacy, delivery and safety and has wide applications in oncology and infectious disease. In particular, nanomedicine has tremendous direct clinical applicability and commercial potential in diagnostics, imaging, treatment and prevention.
Adult Stem Cell-based technologies can be used to regenerate tissue and support native processes leading to tissue repair. It is now well-recognized that adult stem cells can contribute directly to tissue regeneration by differentiation into relevant cell types. There is increasing evidence that Adult Stem Cells also provide remarkable tissue-sparing properties by promoting the growth of resident cells in tissues and by dampening the inflammatory response to tissue injury. Thus, these cells have a variety of clinical applications, ranging from stimulating tissue regeneration to controlling inflammation.
The Fund offers investors the potential for superior returns.
Tommy G. Thompson, former four-term Governor of Wisconsin and Secretary of the United States Department of Health and Human Services (“HHS”) from 2001 to 2005. He is Chairman of the Board of Directors of TherapeuticsMD, Inc., and Physicians Realty Trust (recently had an IPO and follow on secondary offerings all of which were oversubscribed), and a director on a number of publicly and privately held companies. He was the former Chairman of the Board of Directors of AGA Medical Holdings and Logistics Health, Inc. (each of which were successfully sold) and CareView Communications, Inc. He is the former Independent Chairman of the Deloitte Center for Health Solutions and a former partner of the international law firm of Akin Gump Strauss Hauer & Feld.
Gerald J. Elfenbein, M.D., is one of the leading international researchers in the fields of oncology, immunology, and stem cell transplantation. Most recently, he has served as Professor of Medicine at Boston University School of Medicine in Massachusetts, as Director of the Roger Williams Cancer Center (Providence RI), and as the Director of the Blood & Marrow Transplant Program at Roger Williams. Previously, Dr. Elfenbein was the Director of the Bone Marrow Transplant Program and Chief of Bone Marrow Transplant Service at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, FL. He has authored or co-authored over 200 articles, books, and monographs.
Robert Sackstein, M.D., Ph.D., is a Professor in the Departments of Dermatology and Medicine at Harvard Medical School, and is a Physician of the Brigham & Women’s Hospital and the Dana-Farber Cancer Institute in Boston, MA. He is the Director of the Program of Excellence in Glycosciences for the Harvard Medical School, and serves on the Steering Committee of the Regenerative Therapeutics/Tissue Engineering Program of the Biomedical Research Institute of the Brigham & Women’s Hospital. Dr. Sackstein has served on the Scientific Advisory Boards of Wyeth, Genzyme, and GlycoDesign. He currently holds several patents in breakthrough stem cell platform technology.
Mark Kester, Ph.D., is a Professor of Pharmacology and the Director of the Institute for Nanoscale and Quantum Scientific and Technological Advanced Research (nanoSTAR) of the University of Virginia. Dr. Kester’s research interests include the design, characterization and validation of nanotechnologies for targeted drug delivery. His laboratory has evaluated nanoliposomes, nanodendrimers and nanocolloids as effective drug delivery vehicles for pharmacological and molecular agents. His current work focuses on nontoxic nanoscale systemic delivery systems that target mutated tumorigenic proteins. He has founded several companies to commercialize his patented technologies.
David Gilbert, Ph.D., has a long and distinguished career as an entrepreneur, Chief Executive Officer, venture capitalist, investor and corporate director. His career has included; Banking Decision Inc., (Founder and CEO), Mantara, Inc. (CEO, Executive Chairman), Clayton Holdings, Inc. (Board), Erisk (Chairman and CEO), C*ATS Software, Inc. (President), 401Konnect (Founder, President and CEO), California Federal Bank (Executive Chairman during the turnaround). As the CEO, he led California Federal Bank, C*ATS, Erisk, and Banking Business Decision Inc. to very successful exits. Dr. Gilbert has spoken extensively venture investing, and strategic development, and has held faculty appointments at Harvard University and the Wharton School of Finance.
Anthony J. Tether, Ph.D., was the Director of the Defense Advanced Research Projects Agency (DARPA) from 2001 to his retirement in 2009. DARPA is the principal Agency within the Department of Defense for research, development, and demonstration of concepts, devices, and systems that provide highly advanced new technology capabilities. As Director, Dr. Tether was responsible for management of the Agency’s projects for high-payoff, innovative research and development. During Dr. Tether tenure DARPA made grants of close to $25 Billion.
Daniel Tripodi, Ph.D., is the Founder and Partner of the Sage Group and served in a variety of biomedical and biopharmaceutical companies in the areas of technology assessment, business and technology development strategy, and new venture formation. He is also a Founder and Chief Executive Officer of Oraceutics, a new drug discovery platform company utilizing nanotechnology to replace formerly injectable only drugs with oral formulations. Formerly, Dr. Tripodi at Johnson & Johnson was responsible for identifying and forming new ventures, and also held Senior Executive Positions in R&D, Marketing and Strategic Planning in which he played a key role in creating initiatives in Biotechnology that now represent the largest sector in the J&J’s pharmaceutical business.
Brian Glenville, MD, started his business career by advising premier London merchant banks Morgan Grenfell and Deutsche bank on trends in new drug development. At the behest of the Goldman Family he became the medical director of Cardionetics Ltd which was later sold at a significant profit. Dr. Glenville is a venture partner of Meditech Partners and advises other life science venture capital funds. He has been a medical director, member of the Board of Directors, and Chairman of several startup Bio companies that have successfully gone to market. Currently, he is Chairmen of Azurepcr Ltd., a real time PCR company. Dr. Glenville was a pioneer of beating heart surgery and served on “European Union Initiatives” on artificial hearts and transplantation.
Joana Rosario, MD, MPH she was the Deputy Director of the Basic Science Program (BSP), DAIDS, at the National Institutes of Health where she administered a clinical, translational and basic research portfolio through 494 grants and contracts in over 650 sites. She is a respected medical professional with over 35 years of experience as a researcher, educator, government official, and entrepreneur. Dr. Rosario is internationally recognized for her leadership in the areas of strategic clinical research, biomedical education, and effectively establishing public-private partnerships and fostering international partnerships to advance innovation in biotechnology and biomedical research and development.
Granville A. Ungerleider has over thirty years of experience in developing innovative financial structures for healthcare and biopharma companies. He has pioneered, initiated, led and implemented a broad array of initiatives with an emphasis on financial restructurings, mergers and acquisitions, divestitures, private equity investments and public offerings of debt and equity securities during difficult and challenging financial markets. Mr. Ungerleider is the Managing Member of Whitemarsh Capital LLC, a firm that provides strategic and financial advisory services to early stage and mid-sized businesses in the healthcare, alternative energy, and technology industries and Managing Member of Whitemarsh Capital Advisors, LLC, a boutique investment bank.
John Power an experienced financial executive was the former Controller and Chief of Staff for North America for Bank Julius Baer, and recently was President of Mellon Securities, where he integrated Mellon Securities into BNY Mellon. Mr. Power has gained a diverse and deep knowledge of the Financial Services and has turned multiple divisions, in very diverse business lines, from marginal operations into substantial profit contributors.
Matthew P. Duffy is a seasoned BioPharma executive and investor. He was a founding partner of BDR Research Group, LLC, an equity research firm specializing in healthcare and pharmaceutical analysis. As a veteran pharmaceutical executive with extensive development-to-market experience he led the efforts to bring several important new drugs to the commercial realm. At Pfizer, Mr. Duffy was the first Product Manager for Viagra. At Medimmune he led the commercialization of both RespiGam and Synagis with the result that Medimmune’s Market Cap went from $180 Million to over $10 Billion. Mr. Duffy was a member of senior management at Lev Pharmaceuticals where he was responsible for sales, marketing, distribution and the FDA advisory committee which led to Lev with an initial capital of $7 million being sold to ViroPharma for over $500 Million.
Patrick J. Gallagher, CFA, has been an active investor in both private and public healthcare, pharma, biotechnology, therapeutic and device companies for nearly 20 years. He was a founding partner and CEO of BDR Research Group, LLC a healthcare research firm recognized several times by Institutional Investor magazine as a top boutique healthcare equity research firm. BDR also perform extensive high level analytical, consulting, and advisory services for BioPharma companies. Mr. Gallagher served as VP of Business Development to Kinex Pharmaceuticals, a privately held oncology company. His advice, counsel, and guidance are sought out by many of the most prominent institutional healthcare investors.
Joseph M. Braunschek is a Managing Director of Whitemarsh Capital Advisors, LLC. He is an experienced investment banking executive and advisor with a specialization in healthcare, hospital and nursing home financing. He has evaluated and analyzed hundreds of companies and financed over $1 billion of debt. During the recent turbulence in the senior housing finance market his loan portfolios achieved consistent superior returns by having the lowest defaults in the industry.
Daniel R. Berkove specializes in business development, regulatory issues, commercial strategy, and currently advises a number of governments on regulatory issues affecting key areas of national economies. He guided Metal-Tech, an international resource company, to a successful offering on the London AIM market.
Gerald “Gerry” Garcia is responsible for Investor Relations. Currently, he heads Whitemarsh Capital Advisors Institutional sales. Prior to Whitemarsh, Mr. Garcia was Chief of Operations for the State of Connecticut Department Consumer Protection, where he was appointed by Connecticut’s governor to the agency leadership team. He served five years as a New Haven City Councilman where he was a member of the Council’s finance and community development committees and chaired its education committee. In 2015 New Haven Mayor Toni Harp appointed Mr. Garcia to her Taskforce on Community Policing.